PMID- 37266468
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230604
IS  - 1841-9038 (Print)
IS  - 2069-6116 (Electronic)
IS  - 1841-9038 (Linking)
VI  - 18
IP  - 1
DP  - 2023 Mar
TI  - Evaluation of HLA-B*05, *07, *08, *27 and *51 Allele Expression in Adults with 
      Immune Thrombocytopenic Purpura.
PG  - 61-66
LID - 10.26574/maedica.2023.18.1.61 [doi]
AB  - Background: Immune thrombocytopenic purpura (ITP) is an immune mediated acquired 
      disease characterized by isolated thrombocytopenia. Since there is no specific 
      and sensitive biomarkers to guide treatment of ITP patients, this study aimed to 
      evaluate the possible application of human leukocyte alleles HLA-B5, 7, 8, 27 and 
      51 and their association with patients' laboratory data and clinical findings. 
      Methods:Thirty-one adult patients with chronic ITP were included in the present 
      study. Human leukocyte antigen (HLA) typing was done using the standard 
      lymphocytotoxicity HLA typing method. Moreover, patients' medical records were 
      used to collect data about disease presentations, platelet count at diagnosis. 
      Results:Our study included 31 patients (25 females and six males) with a mean age 
      of 40.23+/-17.06 years. Among all participants, HLA-B5 (25.8%) and HLA-B51 (22.6%) 
      alleles were the most prevalent alleles, followed by HLA-B7 (9.7%) and HLA-B8 
      (9.7%), HLA-B27 (3.2%). The mean platelet count significantly was lower in 
      patients with HLA-B5 (16.13x10(3)/muL versus 36.63x10(3)/muL) (P=0.01) and HLA-B51 
      (14.14x10(3)/muL versus 36.24x10(3)/muL) (P=0.04). Also, epistaxis and gingival 
      bleeding were observed in patients with 11.5x10(3)/muL mean platelet count (P=0.04). 
      In addition, lymphocyte and neutrophil cell counts were significantly associated 
      with the expression of HLA-B*05 and HLA-B*51 antigens (P <0.05). 
      Conclusions:According to the present study results, it seems that HLA-B5 and 
      HLA-B51 alongside complete blood count test parameters may have a positive 
      relationship in ITP patients.
FAU - Rad, Niloofar Yazdani
AU  - Rad NY
AD  - Thalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz 
      Jundishapur University of Medical Sciences, Ahvaz, Iran.
FAU - Vosoughi, Tina
AU  - Vosoughi T
AD  - Thalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz 
      Jundishapur University of Medical Sciences, Ahvaz, Iran.
FAU - Ehsanpour, Ali
AU  - Ehsanpour A
AD  - Thalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz 
      Jundishapur University of Medical Sciences, Ahvaz, Iran.
FAU - Saki, Najmaldin
AU  - Saki N
AD  - Thalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz 
      Jundishapur University of Medical Sciences, Ahvaz, Iran.
FAU - Pezeshki, Seyed Mohammad Sadegh
AU  - Pezeshki SMS
AD  - Thalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz 
      Jundishapur University of Medical Sciences, Ahvaz, Iran.
LA  - eng
PT  - Editorial
PL  - Romania
TA  - Maedica (Bucur)
JT  - Maedica
JID - 101526930
PMC - PMC10231164
EDAT- 2023/06/02 13:16
MHDA- 2023/06/02 13:17
PMCR- 2023/03/01
CRDT- 2023/06/02 11:00
PHST- 2023/06/02 13:17 [medline]
PHST- 2023/06/02 13:16 [pubmed]
PHST- 2023/06/02 11:00 [entrez]
PHST- 2023/03/01 00:00 [pmc-release]
AID - 10.26574/maedica.2023.18.1.61 [doi]
PST - ppublish
SO  - Maedica (Bucur). 2023 Mar;18(1):61-66. doi: 10.26574/maedica.2023.18.1.61.